SBBP Strongbridge Biopharma PLC

Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that management will present at the Stifel 2018 Healthcare Conference taking place November 13-14 at the Lotte New York Palace Hotel.

Matthew Pauls, president and chief executive officer of Strongbridge Biopharma, will provide a corporate overview on Tuesday, November 13 at 2:45 p.m. E.T. The presentation will be webcast live and archived on the “Events & Presentations” page in the investor section of the Company’s website at www.strongbridgebio.com.

About Strongbridge BiopharmaStrongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's rare endocrine franchise includes RECORLEV™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing's syndrome, and veldoreotide extended release, a pre-clinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation.  Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company’s rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.

Contacts:

Corporate and Media Relations Elixir Health Public Relations Lindsay Rocco +1 862-596-1304 lrocco@elixirhealthpr.com

Investor Relations U.S.: Solebury Trout Marcy Nanus +1 646-378-2927 mnanus@soleburytrout.com

Europe: First House Geir Arne Drangeid +47 913 10 458 strongbridgebio@firsthouse.no Strongbridge Biopharma plc 900 Northbrook Drive Suite 200 Trevose, PA 19053 Tel. +1 610-254-9200 Fax. +1 215-355-7389